Regeneron CEO says President Trump’s antibody cocktail treatment is ‘case report’ – By Lucas Manfredi (FOX Business) / Oct 11 2020
The US government reached a $450M agreement with Regeneron in July to purchase roughly 300,000 treatment doses of the antibody cocktail
Regeneron CEO Leonard Schleifer said Sunday that the ability of the company’s antibody cocktail that was administered to President Trump to treat a case of coronavirus was merely a “case report” or singular occurrence, despite the president calling the experimental drug a “cure.”
“It is evidence of what’s happening, but it’s kind of the weakest evidence that you can get,” Schiefler told CBS’ “Face the Nation.”
While Schleifer said there are some “very interesting aspects” of the president’s case, such as his age, risk factors and immune system, he argued the real evidence of the drug’s effectiveness will come from the larger, randomized clinical trials which are ongoing and viewed as the “gold standard.”
“We’ve got some preliminary evidence that we’ve talked with the FDA, and we’re going for an emergency use authorization, because we think it’s appropriate at this time,” Schleifer added. “But yes, the president’s case is a case report, perhaps the most analyzed case report ever, but it’s just low down on the evidence scale that we really need.”
Continue to article: https://www.foxbusiness.com/lifestyle/regeneron-ceo-says-antibody-cocktails-treatment-of-president-trump-is-a-case-report
